Celyad Oncology S.A. (CLYYF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Celyad Oncology S.A. (CLYYF) es una empresa del sector Healthcare valorada en 0. La acción obtiene una puntuación de 61/100, una calificación moderada basada en 9 KPI cuantitativos.
Ultimo analisis: 15 mar 2026Celyad Oncology S.A. (CLYYF) Resumen de Asistencia Médica y Tuberías
Celyad Oncology SA, a clinical-stage biopharmaceutical firm, pioneers CAR-T cell therapies for cancer, focusing on allogeneic and autologous approaches. With lead candidates in Phase 1 trials, the company targets metastatic colorectal cancer, multiple myeloma, and acute myeloid leukemia, positioning itself in the competitive oncology therapeutics landscape.
Tesis de Inversión
Celyad Oncology presents a high-risk, high-reward investment opportunity within the CAR-T cell therapy space. The company's focus on allogeneic CAR-T therapies, which offer the potential for off-the-shelf treatments, addresses a key limitation of autologous CAR-T therapies. However, the company's pipeline is still in early stages, with all lead candidates in Phase 1 trials. Successful clinical trial outcomes for CYAD-101, CYAD-211, and CYAD-02 are critical catalysts. The company's high negative profit margin of -3483.3% and gross margin of -134.4% highlight its reliance on future clinical and commercial success. Investment hinges on the potential for Celyad's CAR-T therapies to demonstrate clinical efficacy and safety, secure regulatory approvals, and achieve commercial viability. The company's market capitalization of $0.02 billion reflects the speculative nature of its valuation. Upcoming data releases from ongoing clinical trials will be crucial in determining the company's future prospects.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Celyad Oncology is a clinical-stage biopharmaceutical company focused on CAR-T cell therapies for cancer treatment.
- The company's lead product candidate, CYAD-101, is in Phase 1b clinical trial for metastatic colorectal cancer.
- CYAD-211, an shRNA-based allogeneic CAR-T candidate, is in Phase 1 clinical trial for relapsed/refractory multiple myeloma.
- Celyad's pipeline includes both allogeneic and autologous CAR-T approaches, addressing different patient needs.
- The company has a market capitalization of $0.02 billion and operates with a negative profit margin of -3483.3%.
Competidores y Pares
Fortalezas
- Innovative allogeneic CAR-T cell therapy platform.
- Pipeline of CAR-T candidates targeting various cancers.
- Collaborations with leading research institutions and pharmaceutical companies.
- Experienced management team with expertise in CAR-T cell therapy development.
Debilidades
- Early-stage clinical development of its product candidates.
- High cash burn rate and reliance on external funding.
- Limited commercial infrastructure.
- OTC market listing.
Catalizadores
- Upcoming: Data releases from Phase 1b clinical trial of CYAD-101 for metastatic colorectal cancer.
- Upcoming: Data releases from Phase 1 clinical trial of CYAD-211 for relapsed/refractory multiple myeloma.
- Upcoming: Data releases from Phase 1 clinical trial of CYAD-02 for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
- Ongoing: Potential for strategic collaborations or partnerships to advance its CAR-T cell therapy platform.
- Ongoing: Advancement of preclinical candidate CYAD-203 towards clinical development.
Riesgos
- Potential: Unfavorable clinical trial outcomes for its CAR-T candidates.
- Potential: Regulatory hurdles and delays in securing approvals for its therapies.
- Potential: Competition from other companies developing CAR-T cell therapies.
- Ongoing: High cash burn rate and reliance on external funding.
- Ongoing: Limited liquidity and trading volume due to its OTC market listing.
Oportunidades de crecimiento
- Expansion of CYAD-101 into earlier lines of metastatic colorectal cancer treatment: Successful completion of the Phase 1b trial could pave the way for trials in earlier stages of the disease, significantly expanding the addressable patient population. The market for colorectal cancer treatment is substantial, with projections estimating continued growth as global populations age. This expansion would require further clinical trials and regulatory approvals, potentially extending the timeline to commercialization by several years.
- Development of CYAD-211 for other hematologic malignancies beyond multiple myeloma: The shRNA technology used in CYAD-211 could be applied to target other hematologic cancers, creating new market opportunities. The market for hematologic malignancy treatments is highly competitive but offers significant potential for innovative therapies. This expansion would involve preclinical studies and clinical trials, with a timeline of several years before potential commercialization.
- Advancement of CYAD-02 for treatment of myelodysplastic syndromes (MDS): CYAD-02's autologous CAR-T approach could offer a valuable treatment option for patients with relapsed or refractory MDS, an area with significant unmet need. The market for MDS treatments is growing, driven by an aging population and improved diagnostic methods. This advancement depends on successful completion of the Phase 1 trial and subsequent clinical development, with a timeline extending several years.
- Out-licensing or partnering of preclinical candidate CYAD-203 for solid tumor treatment: Celyad could leverage its CYAD-203 program by partnering with a larger pharmaceutical company to accelerate its development and commercialization. The solid tumor market represents a vast opportunity, but it is also highly competitive. A successful partnership could provide Celyad with significant financial resources and expertise, potentially accelerating the timeline to market.
- Strategic collaborations to enhance CAR-T cell therapy platform: Celyad could pursue collaborations to incorporate new technologies or improve its manufacturing processes, enhancing the competitiveness of its CAR-T cell therapy platform. The CAR-T cell therapy field is rapidly evolving, and collaborations can provide access to cutting-edge technologies and expertise. These collaborations could involve licensing agreements, joint research programs, or acquisitions, with varying timelines and potential impact.
Oportunidades
- Expansion of its CAR-T cell therapy platform to new cancer targets.
- Out-licensing or partnering of its product candidates.
- Securing regulatory approvals for its CAR-T therapies.
- Advancing its preclinical pipeline to clinical development.
Amenazas
- Competition from other companies developing CAR-T cell therapies.
- Regulatory hurdles and delays in clinical development.
- Unfavorable clinical trial outcomes.
- Patent disputes and intellectual property challenges.
Ventajas competitivas
- Proprietary allogeneic CAR-T cell therapy platform.
- Intellectual property rights covering its CAR-T technologies.
- Clinical data supporting the safety and efficacy of its CAR-T candidates.
- Collaborations with leading research institutions and pharmaceutical companies.
Acerca de CLYYF
Founded in 2004 and headquartered in Mont-Saint-Guibert, Belgium, Celyad Oncology SA is a biopharmaceutical company dedicated to the discovery and development of innovative cancer treatments using chimeric antigen receptor T (CAR-T) cell therapies. The company's initial focus was on autologous CAR-T therapies, but it has since expanded to include allogeneic CAR-T approaches, aiming to address the limitations of personalized medicine by creating off-the-shelf therapies. Celyad's lead product candidates include CYAD-101, an allogeneic CAR-T candidate currently in Phase 1b clinical trial for metastatic colorectal cancer. CYAD-211, another allogeneic CAR-T candidate utilizing short hairpin RNA (shRNA) technology, is in Phase 1 clinical trial for relapsed/refractory multiple myeloma. CYAD-02, an autologous CAR-T candidate, is in Phase 1 clinical trial for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical pipeline features CYAD-203, a non-gene edited allogeneic CAR-T candidate designed to co-express interleukin-18 and NKG2D ligands for solid tumor treatment. Celyad Oncology collaborates with other companies, including a licensing agreement with Novartis International AG for allogeneic CAR-T cell patents and a research and development collaboration with Horizon Discovery Group plc for shRNA technology. Formerly known as Celyad SA, the company rebranded to Celyad Oncology SA in June 2020 to reflect its singular focus on oncology. Despite its innovative approach, Celyad faces challenges common to clinical-stage biopharmaceutical companies, including funding, regulatory hurdles, and clinical trial success.
Qué hacen
- Develop allogeneic CAR-T cell therapies for cancer treatment.
- Develop autologous CAR-T cell therapies for cancer treatment.
- Conduct Phase 1 clinical trials for CYAD-101 in metastatic colorectal cancer.
- Conduct Phase 1 clinical trials for CYAD-211 in relapsed/refractory multiple myeloma.
- Conduct Phase 1 clinical trials for CYAD-02 in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
- Advance preclinical candidate CYAD-203 for solid tumor treatment.
- Collaborate with other companies to enhance its CAR-T cell therapy platform.
Modelo de Negocio
- Focus on research and development of CAR-T cell therapies.
- Out-license or partner its technologies and product candidates.
- Generate revenue through licensing agreements and collaborations.
- Potentially generate revenue through commercial sales of approved CAR-T therapies in the future.
Contexto de la Industria
Celyad Oncology operates in the rapidly evolving biotechnology sector, specifically within the CAR-T cell therapy market. This market is characterized by intense competition and high levels of innovation, with companies like Novartis and Gilead already having approved CAR-T therapies. The CAR-T cell therapy market is projected to reach billions of dollars in the coming years, driven by the increasing prevalence of cancer and the limitations of traditional treatments. Celyad's focus on allogeneic CAR-T therapies positions it to potentially capture a significant share of the market by offering off-the-shelf treatments, but it faces competition from other companies developing similar approaches, such as ADTX and ALLR. The success of Celyad depends on its ability to differentiate its therapies through improved efficacy, safety, and cost-effectiveness.
Clientes Clave
- Patients with metastatic colorectal cancer.
- Patients with relapsed/refractory multiple myeloma.
- Patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
- Pharmaceutical companies interested in licensing or partnering with Celyad.
Finanzas
Gráfico e información
Precio de la acción de Celyad Oncology S.A. (CLYYF): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para CLYYF.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CLYYF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CLYYF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CLYYF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Competidores y Pares
Liderazgo: Matthew R. Kane
CEO
Matthew R. Kane serves as the Chief Executive Officer of Celyad Oncology SA. His background includes extensive experience in the biopharmaceutical industry, with a focus on oncology and cell therapy development. Prior to joining Celyad, he held leadership positions at various biotechnology companies, where he was responsible for overseeing clinical development programs, regulatory submissions, and commercialization strategies. He has a strong track record of driving innovation and building successful teams in the biopharmaceutical sector. His expertise spans across various therapeutic areas, including oncology, immunology, and cell therapy.
Historial: Since assuming the role of CEO, Matthew R. Kane has focused on advancing Celyad Oncology's pipeline of CAR-T cell therapies. Key initiatives include progressing CYAD-101, CYAD-211, and CYAD-02 through clinical trials and securing collaborations to enhance the company's technology platform. He has also been instrumental in managing the company's financial resources and navigating the challenges of operating in the competitive CAR-T cell therapy market.
Información del mercado OTC de CLYYF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Celyad Oncology may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies on the OTC Other tier may have limited financial information available, and trading activity can be sporadic and less liquid compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited transparency and regulatory oversight. This contrasts sharply with NYSE/NASDAQ listings, which demand rigorous financial reporting and governance standards. The OTC Other tier is often populated by shell companies, bankrupt entities, or companies with questionable operations.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited liquidity and trading volume on the OTC market.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight and transparency.
- Higher risk of delisting or trading suspension.
- Limited availability of financial information and company disclosures.
- Verify the company's legal status and registration.
- Review available financial statements and disclosures.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Focus on clinical-stage biopharmaceutical development.
- Presence of a CEO and management team.
- Ongoing clinical trials for its product candidates.
- Collaborations with research institutions and pharmaceutical companies.
- History as a publicly traded company (formerly Celyad SA).
Lo Que los Inversores Preguntan Sobre Celyad Oncology S.A. (CLYYF)
¿Cuáles son los factores clave para evaluar CLYYF?
Celyad Oncology S.A. (CLYYF) actualmente tiene una puntuación IA de 61/100, indicando puntuación moderada. Fortaleza clave: Innovative allogeneic CAR-T cell therapy platform.. Riesgo principal a monitorear: Potential: Unfavorable clinical trial outcomes for its CAR-T candidates.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CLYYF?
CLYYF actualmente puntúa 61/100 (Grado B) en el MoonshotScore, lo que sugiere calificación moderada. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CLYYF?
Los precios de CLYYF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CLYYF?
La cobertura de analistas para CLYYF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CLYYF?
Las categorías de riesgo para CLYYF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Unfavorable clinical trial outcomes for its CAR-T candidates.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CLYYF?
La relación P/E para CLYYF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CLYYF sobrevalorada o infravalorada?
Determinar si Celyad Oncology S.A. (CLYYF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CLYYF?
Celyad Oncology S.A. (CLYYF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.